Quidel (OTC:QDEL +2.5%) has completed its investigation of a report from a testing location in Vermont of false positives generated by its Sofia SARS Antigen FIA (fluorescent immunoassay) run on the Sofia 2 instrument.
The company says it found no testing site- or product-related problems with either.
It looked into matter after receiving a complaint that certain patients tested positive with its test who later tested negative using a molecular test (PCR).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.